Aligos Therapeutics (ALGS) Competitors $11.33 +0.35 (+3.19%) Closing price 04:00 PM EasternExtended Trading$11.03 -0.30 (-2.65%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. HUMA, SOPH, FENC, TLSA, AVTE, PRQR, TRDA, SGMT, ENGN, and GNFTShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Humacyte (HUMA), SOPHiA GENETICS (SOPH), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Aerovate Therapeutics (AVTE), ProQR Therapeutics (PRQR), Entrada Therapeutics (TRDA), Sagimet Biosciences (SGMT), enGene (ENGN), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Humacyte SOPHiA GENETICS Adherex Technologies Tiziana Life Sciences Aerovate Therapeutics ProQR Therapeutics Entrada Therapeutics Sagimet Biosciences enGene GENFIT Aligos Therapeutics (NASDAQ:ALGS) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Do institutionals & insiders hold more shares of ALGS or HUMA? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 4.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 5.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ALGS or HUMA more profitable? Humacyte has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Humacyte's return on equity of 0.00% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-2,337.24% -22.41% -12.09% Humacyte N/A N/A -78.26% Do analysts prefer ALGS or HUMA? Aligos Therapeutics currently has a consensus target price of $50.00, indicating a potential upside of 341.31%. Humacyte has a consensus target price of $9.75, indicating a potential upside of 537.25%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Humacyte 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, ALGS or HUMA? Aligos Therapeutics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.94M17.69-$131.21M-$19.79-0.57Humacyte$1.57M154.34-$148.70M-$0.45-3.40 Which has more risk and volatility, ALGS or HUMA? Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Does the media refer more to ALGS or HUMA? In the previous week, Humacyte had 9 more articles in the media than Aligos Therapeutics. MarketBeat recorded 12 mentions for Humacyte and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.16 beat Humacyte's score of -0.23 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHumacyte beats Aligos Therapeutics on 9 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.68M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-0.5721.2230.8326.39Price / Sales17.69206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book0.688.0710.106.62Net Income-$131.21M-$54.08M$3.26B$265.42M7 Day Performance28.02%3.94%3.90%3.58%1 Month Performance24.10%3.02%3.73%0.46%1 Year Performance-13.51%6.84%37.68%19.41% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.4794 of 5 stars$11.33+3.2%$50.00+341.3%-17.8%$69.68M$3.94M-0.5790Positive NewsGap DownHUMAHumacyte2.1372 of 5 stars$1.50-5.1%$10.64+609.5%-79.1%$250.23M$1.57M-3.33150Analyst ForecastSOPHSOPHiA GENETICS2.9365 of 5 stars$3.45-4.4%$8.00+131.9%-9.6%$243.96M$65.17M-7.84520Positive NewsFENCAdherex Technologies1.9143 of 5 stars$8.65-0.1%$13.33+54.1%+48.6%$240.87M$47.54M-20.5910Analyst RevisionTLSATiziana Life Sciences0.8404 of 5 stars$1.96-4.9%N/A+54.5%$240.71MN/A0.008AVTEAerovate TherapeuticsN/A$8.23+11.5%N/A-88.4%$238.55MN/A-2.7520High Trading VolumePRQRProQR Therapeutics2.6521 of 5 stars$2.25-0.4%$8.00+255.6%+6.8%$237.78M$16.49M-4.89180Positive NewsTRDAEntrada Therapeutics3.1426 of 5 stars$5.63-8.3%$25.67+355.9%-66.8%$233.55M$210.78M-3.16110SGMTSagimet Biosciences2.9664 of 5 stars$7.08-0.4%$25.67+262.5%+127.3%$231.23M$2M-3.878Gap DownENGNenGene3.1139 of 5 stars$4.30-0.5%$23.29+441.5%-32.7%$220.77MN/A-2.6131GNFTGENFIT2.1151 of 5 stars$4.19-4.5%$9.00+115.1%-6.6%$219.08M$76.77M0.00120Positive NewsGap Down Related Companies and Tools Related Companies Humacyte Competitors SOPHiA GENETICS Competitors Adherex Technologies Competitors Tiziana Life Sciences Competitors Aerovate Therapeutics Competitors ProQR Therapeutics Competitors Entrada Therapeutics Competitors Sagimet Biosciences Competitors enGene Competitors GENFIT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access